Lead Testing — CPB 0553 | AETNA Coverage Update

Aetna modified CPB 0553 covering lead testing under CPT 83655, effective November 27, 2025. Here's what billing teams need to know.

Aetna updated its lead testing coverage policy — Clinical Policy Bulletin CPB 0553 — with a November 27, 2025 effective date. The update refines medical necessity criteria for blood lead testing and lead screening across multiple patient populations. CPT 83655 is the single billable code under this policy, and whether your claim gets paid hinges entirely on pairing it with the right diagnosis codes.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Lead Testing — CPB 0553
Policy Code	CPB 0553
Change Type	Modified
Effective Date	November 27, 2025

Editorial note: This policy most commonly affects billing in pediatrics, OB/GYN, occupational medicine, primary care, and laboratory settings. Medium financial exposure for practices with high lead testing volume.

---

Aetna Lead Testing Coverage Criteria and Medical Necessity Requirements 2025

Aetna's CPB 0553 draws a clear line between covered blood lead testing and covered lead screening. These are not the same thing, and mixing them up is the fastest route to a claim denial.

Blood lead testing — diagnostic use of CPT 83655 — meets medical necessity for two groups. First, any patient presenting with signs or symptoms of lead poisoning: lowered IQ scores, decreased attention span, impaired hearing, speech or developmental delays, abdominal pain, headaches, vomiting, or constipation. Your ICD-10-CM coding needs to reflect those symptoms directly. Relevant codes include abdominal pain (R10.0–R10.13, R10.30–R10.829, R10.84–R10.9), headache (R51.0–R51.9), constipation (K59.0–K59.9), hearing loss (H90.0–H91.93), and developmental delays (F80.0–F89, R62.0–R62.29).

Second, blood lead testing is medically necessary for pregnant or lactating women — but only when they have documented risk factors for lead exposure. Code O26.891–O26.899 covers lead exposure in pregnancy. Routine blood lead testing for average-risk pregnant women without risk factors does not meet medical necessity under this policy. That distinction will drive denials if your OB or midwifery teams aren't documenting exposure risk in the chart.

Lead screening is a separate coverage track under CPB 0553. Aetna covers it in two situations: occupational lead exposure and pediatric preventive screening for high-risk children.

For occupational screening, OSHA mandates lead testing for workers with workplace lead exposures. Bill CPT 83655 with the appropriate occupational exposure diagnosis. Watch your benefit plan language here — some Aetna plans exclude medical services required for work. Check the member's plan before submitting.

For pediatric preventive screening, Aetna follows the CDC, USPSTF, AAP, and American Academy of Neurology (AAN) guidelines. Coverage applies to preschool-age children in high-risk groups. The policy lists 15 specific risk criteria — not a general "at-risk" catchall. Children must fall into at least one of those defined categories. Some Aetna plans also exclude preventive services entirely. Verify plan benefits before billing.

Prior authorization requirements are not explicitly called out in this policy, but benefit plan-level exclusions for both occupational services and preventive services make pre-billing verification non-negotiable here.

---

Aetna Lead Testing Exclusions and Non-Covered Indications

This is the section that will generate the most denial volume if your lab or ordering providers aren't aligned.

Aetna considers measurement of lead in bone, hair, teeth, or urine experimental, investigational, or unproven. The policy states that the effectiveness of these specimen types has not been established. CPT 83655 explicitly excludes these specimen sources — the code description in CPB 0553 reads: "Lead [not covered for measurement of lead in bone, hair, teeth, or urine]."

If your lab receives orders for lead testing from specimens other than blood, those claims will not be covered. Full stop. This isn't an ambiguous gray area.

There's also a specific retesting situation worth flagging. The FDA recalled the Magellan Diagnostics LeadCare Lead Test Analyzer. The CDC recommends retesting for two groups:

#	Excluded Procedure Copy
1	Children under age six at the time of the May 17, 2017 alert, who had a venous blood lead result under 10 μg/dL analyzed on a Magellan device
2	Currently pregnant or lactating women whose prior test used a Magellan analyzer

These retests are not experimental — they're a recognized clinical need. Document the indication for retesting clearly in the chart and on the claim.

---

Coverage Indications at a Glance

---

Aetna Lead Testing Billing Guidelines and Action Items 2025

The real issue with lead testing billing is specificity. Generic ICD-10 coding will not hold up under Aetna's CPB 0553 criteria. Here's what to do before November 27, 2025.

Copy Action Items

If your practice has a high volume of lead testing billing — especially in pediatrics, OB, or occupational medicine — loop in your compliance officer before November 27, 2025 to review your charge capture and documentation workflows against the updated criteria.

---

CPT, HCPCS, and ICD-10 Codes for Lead Testing Under CPB 0553

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
83655	CPT	Lead [not covered for measurement of lead in bone, hair, teeth, or urine]

Key ICD-10-CM Diagnosis Codes

The full ICD-10-CM list in CPB 0553 contains 220 codes. The codes above represent the primary diagnostic categories most relevant to claim submission for CPT 83655. Review the full policy at CPB 0553 on PayerPolicy for the complete code set.

---